ResMed (NYSE:RMD) Research Coverage Started at UBS Group

UBS Group started coverage on shares of ResMed (NYSE:RMD – Get Rating) in a report published on Monday morning, The Fly reports. The firm issued a buy rating and a $290.00 price objective on the medical equipment provider’s stock.

A number of other equities analysts have also issued reports on RMD. William Blair reiterated an outperform rating on shares of ResMed in a research report on Tuesday, January 31st. StockNews.com began coverage on shares of ResMed in a research report on Thursday, May 18th. They issued a buy rating for the company. Mizuho began coverage on shares of ResMed in a research report on Thursday, April 13th. They issued a buy rating and a $255.00 target price for the company. Finally, JPMorgan Chase & Co. increased their target price on shares of ResMed from $245.00 to $260.00 and gave the company an overweight rating in a research report on Friday, January 27th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of Moderate Buy and a consensus target price of $263.43.

ResMed Stock Down 1.6 %

ResMed stock opened at $216.97 on Monday. The company has a 50-day simple moving average of $223.86 and a 200-day simple moving average of $220.16. The firm has a market capitalization of $31.88 billion, a P/E ratio of 36.96, a P/E/G ratio of 3.33 and a beta of 0.48. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.74 and a current ratio of 3.07. ResMed has a one year low of $194.30 and a one year high of $247.65.

ResMed (NYSE:RMD – Get Rating) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $1.68 EPS for the quarter, topping the consensus estimate of $1.58 by $0.10. The business had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.05 billion. ResMed had a net margin of 21.49% and a return on equity of 25.82%. The company’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.32 earnings per share. As a group, equities analysts expect that ResMed will post 6.48 earnings per share for the current year.

ResMed Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 15th. Shareholders of record on Thursday, May 11th will be issued a $0.44 dividend. This represents a $1.76 dividend on an annualized basis and a yield of 0.81%. The ex-dividend date is Wednesday, May 10th. ResMed’s payout ratio is 29.98%.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 5,675 shares of the stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $206.95, for a total value of $1,174,441.25. Following the completion of the sale, the chief executive officer now directly owns 436,900 shares of the company’s stock, valued at $90,416,455. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Michael J. Farrell sold 5,675 shares of the stock in a transaction that occurred on Wednesday, March 15th. The shares were sold at an average price of $206.95, for a total value of $1,174,441.25. Following the completion of the sale, the chief executive officer now directly owns 436,900 shares of the company’s stock, valued at $90,416,455. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kaushik Ghoshal sold 500 shares of the firm’s stock in a transaction that occurred on Monday, May 1st. The shares were sold at an average price of $239.30, for a total transaction of $119,650.00. Following the transaction, the insider now directly owns 12,704 shares in the company, valued at approximately $3,040,067.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,951 shares of company stock valued at $7,143,067. 1.39% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ResMed

Large investors have recently bought and sold shares of the business. Cambridge Investment Research Advisors Inc. grew its stake in ResMed by 15.7% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 3,050 shares of the medical equipment provider’s stock worth $740,000 after buying an additional 414 shares during the last quarter. Cibc World Market Inc. grew its stake in shares of ResMed by 13.0% during the first quarter. Cibc World Market Inc. now owns 1,000 shares of the medical equipment provider’s stock valued at $243,000 after purchasing an additional 115 shares during the last quarter. Vontobel Holding Ltd. grew its stake in shares of ResMed by 14.5% during the first quarter. Vontobel Holding Ltd. now owns 8,112 shares of the medical equipment provider’s stock valued at $2,020,000 after purchasing an additional 1,025 shares during the last quarter. Sei Investments Co. grew its stake in shares of ResMed by 7.8% during the first quarter. Sei Investments Co. now owns 40,740 shares of the medical equipment provider’s stock valued at $9,781,000 after purchasing an additional 2,955 shares during the last quarter. Finally, Prudential PLC bought a new stake in shares of ResMed during the first quarter valued at approximately $694,000. 64.73% of the stock is currently owned by institutional investors.

ResMed Company Profile

(Get Rating)

ResMed, Inc engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments.